HMG

HMG, human menopausal gonadotropin (also called menotropin), is an injectable fertility medication prepared from the urine of postmenopausal women. Its defining characteristic is that it contains both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity in roughly equal measure; in modern highly purified preparations the LH component is provided substantially by human chorionic gonadotropin (hCG), which acts on the same receptor as LH ^[1]. This dual activity distinguishes HMG from recombinant FSH products, which supply FSH alone ^[1][7].

Historically, menotropins were among the first effective gonadotropin therapies for infertility and have been in clinical use for decades, evolving from crude urinary extracts to highly purified formulations. In women, HMG is used for controlled ovarian stimulation, recruiting and maturing multiple ovarian follicles during in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) cycles, and for ovulation induction. Comparative trials and meta-analyses show that highly purified HMG achieves ongoing pregnancy and live birth rates broadly similar to recombinant FSH, with some analyses of specific protocols suggesting advantages in embryo quality or live birth for HMG owing to its LH activity ^[2][3][7].

In men, HMG has an important role in secondary (hypogonadotropic) hypogonadism, where the pituitary fails to produce adequate gonadotropins. Combined with hCG, HMG supplies the FSH signal to Sertoli cells that, alongside the high intratesticular testosterone driven by hCG, is required for full spermatogenesis; large cohort studies show this combination can induce sperm production and pregnancies in men who were previously azoospermic ^[4][5]. Evidence also indicates that although hCG alone can maintain spermatogenesis once it is established, FSH activity from HMG is needed for quantitatively normal sperm output ^[6]. HMG is a prescription medicine given by injection.

HMG (menotropin) supplies FSH and LH activity, and its principal risk in women is ovarian hyperstimulation syndrome, which can range from mild to a serious condition with fluid shifts, enlarged ovaries, and thromboembolism, along with an increased chance of multiple pregnancy. Injection-site reactions and, in men, gynecomastia can occur. Because it potently stimulates the reproductive axis, it requires medical monitoring rather than casual use.

Menotropins (human menopausal gonadotropins) contain both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) and carry no documented metabolic or pharmacokinetic interactions with other medications; their primary clinical consideration is gonadal response modulation.

In patients with polycystic ovary syndrome, menotropin stimulation produces significantly elevated Anti-Mullerian Hormone (MIS) levels in both follicular fluid and serum compared to patients with tubal factor infertility, resulting in a higher proportion of immature oocytes (17.9% versus 1.5%) and reduced fertilization rates (30.2% versus 62.2%), reflecting altered follicle dynamics rather than a true drug interaction. ^[27] No significant pharmacokinetic interactions occur with concurrent fertility medications or standard concomitant therapies, though individualized dosing based on ovarian response monitoring is standard practice to optimize safety and efficacy.

Checking a whole stack? Run it through interactions + stacks.

Human menopausal gonadotropin emerged from work in the 1950s by the endocrinologist Bruno Lunenfeld together with the chemist Piero Donini, who developed a method to extract the gonadotropins FSH and LH from the urine of postmenopausal women, a naturally rich source of these hormones. The first purified preparation, marketed as Pergonal by the company Serono, made large-scale therapy possible, and Lunenfeld reported the first pregnancies achieved through HMG-induced ovulation in the early 1960s. This breakthrough established gonadotropin therapy as a foundation of assisted reproduction, and Lunenfeld is widely regarded as a pioneer of modern reproductive endocrinology ^[1]. Menotropins have since remained a standard tool for both ovarian stimulation and the treatment of male hypogonadotropic hypogonadism.

HMG is regarded as a durable workhorse of fertility medicine, valued because it delivers both FSH and LH activity in a single agent rather than FSH alone. In IVF it matches recombinant FSH on live birth rates, and some protocols suggest an edge for HMG in embryo quality, while in men with hypogonadotropic hypogonadism it pairs with hCG to restore testosterone and induce sperm production, offering a genuine path to fatherhood. Clinicians appreciate its long and well-documented track record. In fairness, it is an injectable therapy that requires careful monitoring, carries the risks of ovarian hyperstimulation and multiple pregnancy common to all gonadotropins, and is the subject of an ongoing urine-derived versus recombinant preparation debate.